Cargando…

Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality

BACKGROUND: Vancomycin is one of the most common therapeutic agents for treating gram-positive infections, particularly in critically ill patients. The aim of this study was to identify factors associated with initial therapeutic vancomycin trough levels and mortality in a tertiary-care intensive ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshehri, Nadiyah, Ahmed, Anwar E, Yenugadhati, Nagarajkumar, Javad, Sundas, Al Sulaiman, Khalid, M Al-Dorzi, Hasan, Aljerasiy, Majed, Badri, Motasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569025/
https://www.ncbi.nlm.nih.gov/pubmed/33116547
http://dx.doi.org/10.2147/TCRM.S266295
_version_ 1783596641409826816
author Alshehri, Nadiyah
Ahmed, Anwar E
Yenugadhati, Nagarajkumar
Javad, Sundas
Al Sulaiman, Khalid
M Al-Dorzi, Hasan
Aljerasiy, Majed
Badri, Motasim
author_facet Alshehri, Nadiyah
Ahmed, Anwar E
Yenugadhati, Nagarajkumar
Javad, Sundas
Al Sulaiman, Khalid
M Al-Dorzi, Hasan
Aljerasiy, Majed
Badri, Motasim
author_sort Alshehri, Nadiyah
collection PubMed
description BACKGROUND: Vancomycin is one of the most common therapeutic agents for treating gram-positive infections, particularly in critically ill patients. The aim of this study was to identify factors associated with initial therapeutic vancomycin trough levels and mortality in a tertiary-care intensive care unit (ICU). METHODS: This retrospective study evaluated 301 adult ICU patients admitted to King Abdulaziz Medical City in Riyadh between October 1, 2017 and December 31, 2018 with confirmed gram-positive infections and received intravenous vancomycin. Vancomycin trough levels of 15–20 mg/L for severe infections and 10–15 mg/L for less severe infections were considered therapeutic. RESULTS: The patients were relatively older with a mean age of 60 (SD ±20) years. Initial vancomycin trough levels were therapeutic in 168 (55.8%). Factors associated with initial therapeutic vancomycin trough levels were female gender (adjusted odds ratio [aOR]=2.575), older age (aOR=1.024), receiving a loading dose (aOR=2.445), having bacteremia (aOR=2.061), and high platelet count (aOR=1.003). On the other hand, the increase of estimated glomerular filtration rate (eGFR) (aOR=0.993) and albumin levels (aOR=0.944) were associated with lower odds of initial therapeutic vancomycin trough levels. Factors associated with higher mortality were female gender (adjusted hazard ratio [aHR]=2.630), increased body weight (aHR=1.021), cancer (aHR=3.451), and high APACHE II score (aHR=1.068). CONCLUSION: The study identified several factors associated with achieving initial therapeutic vancomycin trough levels (i.e. older age, female gender, receiving a loading dose, bacteremia, high platelets count, low eGFR and albumin level). These factors should be considered in the dosing of vancomycin in critically ill patients with gram-positive infections.
format Online
Article
Text
id pubmed-7569025
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75690252020-10-27 Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality Alshehri, Nadiyah Ahmed, Anwar E Yenugadhati, Nagarajkumar Javad, Sundas Al Sulaiman, Khalid M Al-Dorzi, Hasan Aljerasiy, Majed Badri, Motasim Ther Clin Risk Manag Original Research BACKGROUND: Vancomycin is one of the most common therapeutic agents for treating gram-positive infections, particularly in critically ill patients. The aim of this study was to identify factors associated with initial therapeutic vancomycin trough levels and mortality in a tertiary-care intensive care unit (ICU). METHODS: This retrospective study evaluated 301 adult ICU patients admitted to King Abdulaziz Medical City in Riyadh between October 1, 2017 and December 31, 2018 with confirmed gram-positive infections and received intravenous vancomycin. Vancomycin trough levels of 15–20 mg/L for severe infections and 10–15 mg/L for less severe infections were considered therapeutic. RESULTS: The patients were relatively older with a mean age of 60 (SD ±20) years. Initial vancomycin trough levels were therapeutic in 168 (55.8%). Factors associated with initial therapeutic vancomycin trough levels were female gender (adjusted odds ratio [aOR]=2.575), older age (aOR=1.024), receiving a loading dose (aOR=2.445), having bacteremia (aOR=2.061), and high platelet count (aOR=1.003). On the other hand, the increase of estimated glomerular filtration rate (eGFR) (aOR=0.993) and albumin levels (aOR=0.944) were associated with lower odds of initial therapeutic vancomycin trough levels. Factors associated with higher mortality were female gender (adjusted hazard ratio [aHR]=2.630), increased body weight (aHR=1.021), cancer (aHR=3.451), and high APACHE II score (aHR=1.068). CONCLUSION: The study identified several factors associated with achieving initial therapeutic vancomycin trough levels (i.e. older age, female gender, receiving a loading dose, bacteremia, high platelets count, low eGFR and albumin level). These factors should be considered in the dosing of vancomycin in critically ill patients with gram-positive infections. Dove 2020-10-14 /pmc/articles/PMC7569025/ /pubmed/33116547 http://dx.doi.org/10.2147/TCRM.S266295 Text en © 2020 Alshehri et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Alshehri, Nadiyah
Ahmed, Anwar E
Yenugadhati, Nagarajkumar
Javad, Sundas
Al Sulaiman, Khalid
M Al-Dorzi, Hasan
Aljerasiy, Majed
Badri, Motasim
Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality
title Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality
title_full Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality
title_fullStr Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality
title_full_unstemmed Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality
title_short Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality
title_sort vancomycin in icu patients with gram-positive infections: initial trough levels and mortality
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569025/
https://www.ncbi.nlm.nih.gov/pubmed/33116547
http://dx.doi.org/10.2147/TCRM.S266295
work_keys_str_mv AT alshehrinadiyah vancomycininicupatientswithgrampositiveinfectionsinitialtroughlevelsandmortality
AT ahmedanware vancomycininicupatientswithgrampositiveinfectionsinitialtroughlevelsandmortality
AT yenugadhatinagarajkumar vancomycininicupatientswithgrampositiveinfectionsinitialtroughlevelsandmortality
AT javadsundas vancomycininicupatientswithgrampositiveinfectionsinitialtroughlevelsandmortality
AT alsulaimankhalid vancomycininicupatientswithgrampositiveinfectionsinitialtroughlevelsandmortality
AT maldorzihasan vancomycininicupatientswithgrampositiveinfectionsinitialtroughlevelsandmortality
AT aljerasiymajed vancomycininicupatientswithgrampositiveinfectionsinitialtroughlevelsandmortality
AT badrimotasim vancomycininicupatientswithgrampositiveinfectionsinitialtroughlevelsandmortality